Abstract
The editorial, “Clinical and translational mode of single-cell measurements: An
artificial intelligent single-cell,” introduces the innovative clinical artificial intelligence
single-cell (caiSC) system, which merges AI with single-cell informatics
to advance real-time diagnostics, disease monitoring, and treatment prediction.
By combining clinical data and multimodal molecular inputs, caiSC facilitates
personalized medicine, promising enhanced diagnostic precision and tailored
therapeutic approaches. Despite its potential, caiSC lacks comprehensive data
coverage across cell types and diseases, presenting challenges in data quality
and model robustness. The article explores development strategies such as data
expansion, machine learning advancements, and interpretability improvements.
Future applications of caiSC could include digital cell twins, offering in-depth
simulations of cellular behavior to support drug discovery and personalized
treatments. Regulatory considerations are discussed, underscoring the need for
SaMD/AIaMD certifications for clinical use. Ultimately,with further refinement,
caiSC could transform clinical decision-making, driving personalized, precision
medicine, and improved patient outcomes.
artificial intelligent single-cell,” introduces the innovative clinical artificial intelligence
single-cell (caiSC) system, which merges AI with single-cell informatics
to advance real-time diagnostics, disease monitoring, and treatment prediction.
By combining clinical data and multimodal molecular inputs, caiSC facilitates
personalized medicine, promising enhanced diagnostic precision and tailored
therapeutic approaches. Despite its potential, caiSC lacks comprehensive data
coverage across cell types and diseases, presenting challenges in data quality
and model robustness. The article explores development strategies such as data
expansion, machine learning advancements, and interpretability improvements.
Future applications of caiSC could include digital cell twins, offering in-depth
simulations of cellular behavior to support drug discovery and personalized
treatments. Regulatory considerations are discussed, underscoring the need for
SaMD/AIaMD certifications for clinical use. Ultimately,with further refinement,
caiSC could transform clinical decision-making, driving personalized, precision
medicine, and improved patient outcomes.
| Originalsprache | englisch |
|---|---|
| Aufsatznummer | e70096 |
| Seiten (von - bis) | 1-5 |
| Seitenumfang | 5 |
| Fachzeitschrift | Clinical and Translational Medicine |
| Jahrgang | 2025 |
| Ausgabenummer | e70096 |
| DOIs |
|
| Publikationsstatus | Veröffentlicht - 6 Jan. 2025 |
Fields of Expertise
- Human- & Biotechnology